文献速递脑血管病

ABCD-GENE评分与氯吡格雷疗效:CHANCE试验二次分析

Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
PubMed 文献 · Stroke · 2021-10-20

该研究为CHANCE试验二次分析,纳入2923例中国轻型卒中或TIA患者,计算ABCD-GENE评分。以10分为界,评分<10者氯吡格雷联合阿司匹林较单用阿司匹林显著降低3个月卒中复发风险,评分≥10者获益不显著。按0-5、6-24、>24分层,氯吡格雷联合阿司匹林疗效随评分升高而降低(趋势P=0.0052)。

要点

  • ABCD-GENE评分<10的轻型卒中/TIA患者,氯吡格雷联合阿司匹林较单用阿司匹林显著降低卒中复发风险。
  • 评分≥10者联合治疗获益不显著,评分越高氯吡格雷疗效越差(趋势P=0.0052)。
  • ABCD-GENE评分整合CYP2C19基因型与临床因素,可用于评估氯吡格雷疗效。

核心结论

  • 在中国轻型卒中/短暂性脑缺血发作人群中,ABCD-GENE评分越高,氯吡格雷联合阿司匹林治疗的疗效越低。
  • ABCD-GENE评分可整合CYP2C19基因型与临床风险因素,用于估计氯吡格雷联合阿司匹林治疗的疗效。

研究设计与样本

  • CHANCE试验的二次分析,共纳入2923例轻型卒中或短暂性脑缺血发作患者。
  • 计算所有患者的ABCD-GENE评分,按建议 cutoff 10 分为高风险与低风险,并进一步分为0-5、6-24和>24三组。
  • 主要结局为3个月卒中复发。

主要发现

  • 2923例患者中,2273例(77.76%)ABCD-GENE评分<10,650例(22.24%)评分≥10。
  • 与单用阿司匹林相比,氯吡格雷联合阿司匹林治疗在评分<10患者中卒中复发风险比为0.70(95%CI 0.54-0.91),在评分≥10患者中为0.76(95%CI 0.46-1.24)。
  • 按评分0-5、6-24、>24分层,氯吡格雷联合阿司匹林治疗卒中复发的风险比分别为0.57(95%CI 0.38-0.85)、0.78(95%CI 0.58-1.06)、1.20(95%CI 0.44-3.28),趋势P=0.0052。

关键数值与推荐

  • ABCD-GENE评分建议 cutoff 值为10,用于区分高血小板反应性高风险患者。
  • 评分分层:0-5、6-24、>24。

临床怎么用

  • 对于轻型卒中或短暂性脑缺血发作患者,可计算ABCD-GENE评分以评估氯吡格雷联合阿司匹林治疗的预期疗效。
  • 评分<10的患者可能从氯吡格雷联合阿司匹林治疗中获益更明显,评分≥10者获益不显著。

局限性

  • 本研究为CHANCE试验的二次分析,结果需在前瞻性研究中进一步验证。
  • 研究人群为中国轻型卒中/短暂性脑缺血发作患者,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The age, body mass index, chronic kidney disease, diabetes, and genotyping (ABCD-GENE) score is a validated risk score integrating CYP2C19 genotypes with clinical risk factors influencing clopidogrel response that would allow the more precise identification of subjects at risk for high platelet reactivity and adverse clinical outcomes. Our objective was to further verify application of the ABCD-GENE score and investigate appropriate cutoff value in patients with minor stroke or transient ischemic attack. METHODS: In this post-analysis of the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), the ABCD-GENE score was calculated for all patients enrolled in this study. By using the proposed cutoff of 10, patients were stratified as being at high risk for high platelet reactivity or not. We further categorized the ABCD-GENE score to 0 to 5, 6 to 24, and >24 to investigate the cutoff value of this scale in clinical application. Stroke recurrence at 3 months was considered as the primary outcome. RESULTS: Among a total of 2923 patients with minor stroke/transient ischemic attack, there were 2273 (77.76%) with ABCD-GENE score <10 and 650 (22.24%) patients with ABCD-GENE score ≥10. Compared with the aspirin alone, hazard ratios (95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 0.70 (0.54-0.91) and 0.76 (0.46-1.24), among patients of ABCD-GENE scores <10 and ABCD-GENE scores ≥10, respectively. Stratified analyses by ABCD-GENE score 0 to 5, 6 to 24, and >24, hazard ratios of the clopidogrel-aspirin therapy for stroke recurrence were 0.57 (95% CI, 0.38-0.85), 0.78 (0.58-1.06), and 1.20 (0.44-3.28) (P value for trend=0.0052). CONCLUSIONS: Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score. Our study suggests that CYP2C19 genotypes and clinical risk factors can be integrated by ABCD-GENE score to estimate the efficacy of clopidogrel-aspirin therapy.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Dai L, Xu J, Yan H, et al. Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. Stroke. 2021. PMID: 34666508. doi:10.1161/STROKEAHA.120.033049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。